Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Baxter
Queensland Health
Mallinckrodt
Colorcon
Chinese Patent Office
Novartis
Harvard Business School
Deloitte
Johnson and Johnson
Merck

Generated: August 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020659

« Back to Dashboard
NDA 020659 describes NORVIR, which is a drug marketed by Abbvie Inc, Abbvie, and Abbott, and is included in five NDAs. It is available from four suppliers. There are eleven patents protecting this drug and two Paragraph IV challenges. Additional details are available on the NORVIR profile page.

The generic ingredient in NORVIR is ritonavir. There are twenty-one drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ritonavir profile page.

Summary for NDA: 020659

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:2
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 020659

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NORVIR
ritonavir
SOLUTION;ORAL 020659 NDA AbbVie Inc. 0074-1940 0074-1940-63 1 BOTTLE in 1 CARTON (0074-1940-63) > 240 mL in 1 BOTTLE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;ORALStrength80MG/ML
Approval Date:Mar 1, 1996TE:RLD:Yes
Patent:► SubscribePatent Expiration:Dec 26, 2016Product Flag?Substance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Dec 26, 2016Product Flag?Substance Flag?Delist Request?

Expired Orange Book Patents for NDA: 020659

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996► Subscribe► Subscribe
Abbvie
NORVIR
ritonavir
SOLUTION;ORAL020659-001Mar 1, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Farmers Insurance
Queensland Health
Healthtrust
Federal Trade Commission
Novartis
Accenture
AstraZeneca
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot